Classical complement pathway inhibition reduces brain damage in a hypoxic ischemic encephalopathy animal model

Area of Science:

• Neuroscience
• Immunology
• Neonatal Research

Background:

• Perinatal hypoxic-ischemic encephalopathy (HIE) is a leading cause of infant mortality and disability.
• The complement system's role in HIE-related ischemia-reperfusion injury is not fully understood.
• RLS-0071 is a novel dual-targeting anti-inflammatory peptide.

Purpose of the Study:

• To investigate the therapeutic potential of RLS-0071 in an animal model of HIE.
• To evaluate the effects of RLS-0071 on acute brain injury and long-term neurocognitive outcomes.
• To explore the role of complement activation in HIE and its modulation by RLS-0071.

Main Methods:

• Utilized a well-established HIE rat pup model.
• Administered interventions including normothermia, hypothermia, and RLS-0071 (with and without hypothermia).
• Assessed histopathological changes, brain C1q levels, neuroimaging (MRI), and neurocognitive function in adolescence.

Main Results:

• RLS-0071 with hypothermia provided neuronal protection (P = 0.048) and reduced brain C1q levels (P = 0.01 at 1hr, P = 0.005 at 8hr with hypothermia).
• MRI showed RLS-0071 and hypothermia reduced lesion volume (P<0.05) and T2 signal (P<0.01) at 24 hours and 21 days, respectively.
• RLS-0071 treatment improved both short-term and long-term memory.

Conclusions:

• RLS-0071 demonstrates neuroprotective effects in the context of HIE.
• Combined therapy of RLS-0071 and hypothermia significantly mitigates brain damage and improves cognitive function.
• Modulation of complement activation by RLS-0071 may be a key mechanism in reducing HIE-induced brain injury.